Login to My NLA Account

All

.webform-client-form { display: none; } 2025 #NLASessions Social Ambassador Form Interested in becoming a #NLASessions Social Ambassador? Fill out the form below to apply! As a Social Ambassador, you’ll help spread the excitement of #NLASessions by sharing key insights, engaging with NLA... more

Lipid Spin is but one NLA educational offering. As editors we are pleased to bring these issues to clinicians on a regular basis. Lipid Spin is peer reviewed. The subject matter is always trying to address how we can better take care of the patients/clients we serve. Our focus is prevention.... more

0
No votes yet

I am honored to be chosen to keep this chair warm for the next year, and excited about the opportunity to serve the NLA, and all the members of the Southwest Chapter.   I am grateful to have received this position after it has been in the excellent care of my predecessor, Judy Collins.... more

Section:
Chapter News: SWLA

0
No votes yet

This Fall 2023 edition of the LipidSpin on Diabesity is sponsored by NELA and SELA Chapters. The 2023 NELA Chapter and Board would like to thank all the authors, contributors, and editors who shared their expertise to make this an informative and valuable issue of LipidSpin. Despite the... more

0
No votes yet

Don’t forget to claim your CME/CE credit from the Annual Scientific Sessions in Las Vegas. You’ll need your NLA membership number to claim credit by the deadline of June 21. If you have questions, call the NLA office or email cme@lipid.org read more more

.btn-about { margin: 10px; } .live-courses { display: flex; align-items: center; justify-content: center; margin-top:20px } .img-responsive { border-radius: 15px; } .anc-course { display: flex; justify-content: center; flex-wrap: wrap... more

0
No votes yet

2026 #NLASessions Pre-Conference Courses     OFFERED IN-PERSON ONLY Wednesday, June 10 | 7:30 AM – 5:20 PM CT Thursday, June 11 | 7:30 AM – 12:30 PM CT $595 NLA Members | $995 Non-Members | Trainees $0 | $1,150 Industry... more

Nonalcoholic fatty liver disease (NAFLD) contributes to cardiovascular disease risk through dyslipidemia, insulin resistance, altered coagulation states, and increased inflammation. NAFLD occurs in greater than 25% of individuals worldwide. Its prevalence is highest in the U.S. Hispanic population... more

0
No votes yet

Two new PCSK9 monoclonal antibodies have been given a nod of approval to the Food and Drug Administration (FDA). The FDA Endocrinologic and Metabolic Drugs Advisory Committee reviewed the evidence on the new class of cholesterol-lowering drugs and recommended that the FDA should approve the new... more